• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Weekly Roundup: September 27-October 1

ICYMI, some of this week’s featured content includes a new Pointers with Dr Portela, and articles on Maui Derm NP+PA coverage, website slander, nail issues plus more.

POLL: What conference are you looking forward to the most?

Legal Eagle: Website Slander

In this month's Legal Eagle column, David J. Goldberg, MD, JD, explores patient reviews and how to handle negative/false reviews that are anonymous.

Hospitals Hit Hard by Delta Variant

Margins in August still low along with many volume metrics.

Galderma, Sofregen Enter Agreement to Develop Silk-based Biostimulators

Galderma and Sofregen Medical announced they have entered into an agreement to co-develop a novel line of silk-based biostimulators that will enable immediate volume restoration and provide structure for new tissue generation.

CBD Acne Skin Care Line Announced

Zelira Therapeutics has announced the launch of RAF FIVE acne treatment product.

Peptides and Their Many Uses

A study published in Molecules explored the vast use of peptides in many therapies that could improve treatments from anti-aging to vaccines.

Nebulous Nail Issues

In this month's Cosmetic Conundrums column, Dermatology Times® Chief Medical Editor Zoe Diana Draelos, MD, dives into the issues of nail care. She explains why nails peel, how to prevent it, and so much more!

Novel Glacial Rx Earns Third FDA Indication

R2 Technologies’ Novel Glacial Rx system has been cleared by the FDA for a new indication.

Early Systemic Glucocorticoid Treatment Suggested Vitiligo

Investigators reported a significant difference in the expansion rate of the skin lesion area in patients with vitiligo in just 3 months of treatment.

EADV Releases Secukinumab Delivery Data

The new data examines delivery system efficacy of either 1 secukinumab 300-mg dose in an autoinjector vs 2 doses of secukinumab 150-mg 1 mL pre-filled syringes.

Maui Derm NP+PA Fall Has Begun

The Maui Derm NP+PA Fall 2021 8th Annual Meeting begins today with an in-person, 4-track preconference program at the Omni Grove Park Inn in Asheville, North Carolina. Continue to check in for the next 3 days for the latest coverage of the main program which is from September 30 to October 3.

Pointers With Dr Portela: What to Ask The Dermatologist at an Acne Visit

In this week’s Pointers with Dr Portela, the 208SkinDoc explains what to ask the dermatologist in an appointment to insure a productive and effective visit.

Tips to Train NPs, PAs in Neuromodulators, Dermal Fillers

Expert panelists outline best practices to set up nurse practitioners (NPs) and physician assistants (PAs) for success in injecting neuromodulators and dermal fillers as part of the preconference track at Maui Derm NP+PA Fall 2021 .

Study: Skin Cancer Detection Apps Fail to Correctly Classify Life-Threatening Cancers

The EADV congress today presents new study data showing that skin cancer detection apps fail to correctly categorize rare and aggressive cancers as high-risk.

ACP Calls for Physician Well-being Support During COVID-19

Physician well-being has taken a beating throughout the COVID-19 pandemic.

Nailing the Nail Diagnosis

As a part of her Maui Derm NP+PA Fall 2021 presentation, Phoebe Rich, MD, discusses how different diseases manifest in the nails, including multiple patient examples, and whether or not biopsy is needed for diagnosis.

New Drugs Tackle Tough Challenges

Potential game-changers in the pipeline and newly FDA-approved treatments were highlighted in an overview of new drugs to watch at Maui Derm NP+PA Fall 2021 meeting.

AK Overview: Current Guidelines and Emerging Therapies

A review of the American Academy of Dermatology guidelines and current treatment improvements for actinic keratosis were discussed during a presentation at Maui Derm NP+PA Fall 2021.

Latest News on Atopic Dermatitis in Children

At Maui Derm NP+PA Fall 2021, Vikash S. Oza, MD, and Matthew J. Zirwas, MD, discuss the current Rx and Dx of atopic dermatitis in children.

What Patients Need to Know About New JAK Topical Inhibitor

Patients with mild to moderate AD have a new topical treatment option, but physicians will need to prepare for some focused conversations about safety.

Natural Ingredient Cream vs Oatmeal Cream for Dry Skin

A study published in the Journal of Drugs in Dermatology compared the efficacy of natural ingredient-based moisturizing cream versus a colloidal oatmeal moisturizing cream.

Coppertone Recalls 12 Lots of Aerosol Sunscreen

Coppertone has issued a voluntary recall for 12 lots of its aerosol sunscreen, citing detected levels of the carcinogen benzene.

SCC and BCC Updates from Maui Derm NP+PA Fall

At Maui Derm NP+PA Fall 2021, George Martin, MD, discussed his opinion on best treatment options for SCC in situ and cutaneous SCC at high risk for metastasis along with BCC that require special considerations.

Psoriasis Updates: Comparing IL-23 and IL-17 Inhibitors, TNF Blockers

In his presentation at Maui Derm NP+PA Fall 2021, Bruce E. Strober, MD, PhD, discusses IL-23 and IL-17 inhibitors, TNF efficacy, and dosing changes in secukinumab.

Using Combination Therapies and Avoiding Subtypes for Rosacea

In this presentation on rosacea from Maui Derm NP+PA Fall 2021, Julie Harper, MD, explains why combination therapy is more effective and how classifying rosacea patients by subtype can lead to suboptimal treatments.

Latest on Infectious Disease at Maui Derm

Ted Rosen, MD, and Sheila Fallon Friedlander, MD, discuss infectious disease updates at the virtual Maui Derm NP+PA Fall 2021 conference.

Related Videos
3 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.